Metabolomics analysis of biofluids is increasingly being recognized as a useful tool for the diagnosis and management of a number of infectious diseases. Here we showed that plasma metabolomics profiling by untargeted 1 H nuclear magnetic resonance may allow the anticipation of the occurrence of cytomegalovirus (CMV) DNAemia in allogeneic stem cell transplant. For this purpose, key discriminatory metabolites were total glutathione, taurine, methylamine, trimethylamine N-oxide and lactate, all of which were upregulated in patients eventually developing CMV DNAemia. The overall classification accuracy (predictability) of the projection to latent structure discriminant analysis (PLS-DA) model in cross-validation technical replicates was 73 %. Increased levels of alanine, lactate and total fatty acids, and a shift in the fatty acid profile towards unsaturated species, were observed in patients with detectable CMV DNA in plasma. The classification accuracy of this PLS-DA model in cross-validation technical replicates was 81 %. Plasma metabolomics profiling may prove useful for identifying patients at highest risk for CMV DNAemia thus allowing early inception of antiviral therapy.
INTRODUCTION
Cytomegalovirus (CMV) infection is a leading cause of morbidity and mortality in allogeneic stem cell transplant recipients (Allo-SCT) (Solano & Navarro, 2010) . In this clinical setting, pre-emptive antiviral therapy is currently the preferred first-choice strategy for the prevention of CMV end-organ disease over universal antiviral prophylaxis (Solano & Navarro, 2010) . Nevertheless, the recent advent of new antivirals such as letermovir and maribavir, with increased intrinsic activity against CMV and better safety profiles with respect to conventional drugs (i.e. ganciclovir and foscarnet) (Boeckh et al., 2015) has renewed interest in antiviral prophylaxis. In that context, the identification of biomarkers predicting the occurrence of CMV viraemia would allow the inception of antiviral prophylaxis on an individual basis according to the patient's risk (targeted prophylaxis) . This strategy might offer advantages over universal prophylaxis, including cost savings.
Metabolomics analysis of biofluids by either targeted or untargeted nuclear magnetic resonance (NMR)-or MSbased methods is being increasingly recognized as a useful tool for the diagnosis, prediction of the clinical course or monitoring of antimicrobial therapy efficacy in a number of infectious diseases, including human immunodeficiency virus infection, malaria, tuberculosis, urinary tract infection, sepsis and congenital CMV infection (Noto et al., 2014; Pacchiarotta et al., 2012) . Furthermore, metabolomics permits the assessment of host-pathogen metabolic interactions from which new therapeutic strategies may be derived (Noto et al., 2014) . The current proof-of-principle study was aimed at determining the potential utility of plasma metabolomics fingerprinting to predict the occurrence of CMV DNAemia in Allo-SCT recipients. We also investigated the effect of CMV replication within episodes of active systemic CMV infection in the plasma metabolome.
RESULTS

Features of CMV DNAemia
The study cohort included a total of 34 patients who developed CMV DNAemia at a median of 28 days after Allo-SCT (range, 2-70 days) and 19 who did not. None of the former patients developed CMV end-organ disease within the study period (the first 100 days after Allo-SCT). The median plasma CMV DNA peak load within episodes of CMV DNAemia was 8370 IU ml 21 (range, 31-182 120 IU ml 21 ). Twenty-three out of 34 episodes were treated pre-emptively with antivirals. In total, 23 episodes had been resolved (CMV DNAemia clearance) at the end of the study period. In this cohort, patients with or without CMV DNAemia did not differ significantly in terms of demographics, type of transplant, stem cell source, conditioning regimen, CMV serostatus of donor and recipient, graft-versus-host disease (GvHD) prophylaxis regimen or incidence of acute GvHD of any severity (not shown).
Plasma metabolomics profile that associates with the presence of CMV DNAemia
To determine whether the presence of CMV DNA in the systemic compartment was associated with a specific plasma metabolomics profile, we analysed NMR spectra of 105 plasma specimens with detectable CMV DNA from 34 patients (test specimens; median CMV DNA load, 5621 IU ml 21 ; range, 556-182 120 IU ml 21 ) and 292 with undetectable levels of CMV DNA obtained within a comparable time frame (control specimens). The former specimens were obtained within the first month following detection of CMV DNAemia at approximately 1-week intervals (median, three specimens per patient; range, two to five specimens per patient). Forty-two metabolites corresponding to non-overlapping and clearly defined peaks of the spectrum were analysed. A chemometric projection to latent structure discriminant analysis (PLS-DA) model (three latent variables) provided a differential global metabolic profile for samples with detectable CMV DNA. The score plots showed that specimens containing CMV DNA were clearly distinguishable from specimens not containing it (Fig. 1a ). The goodness of fit of the model was high with an R 2 X (cumulative) of 0.514 and an R 2 Y (cumulative) of 0.711, and its predictability for discriminating between test and control specimens, as inferred by the cumulative Q 2 (0.592), was good (models with Q 2 i0.4 are considered to reliably predict phenotypic differences between comparative groups). In this context, the fact that the values of the parameters describing the PLS-DA model were positive indicated the existence of a reasonably robust metabolic difference between specimens with or without detectable CMV DNA. The classification accuracy of the model in crossvalidation technical replicates was 81 %, further emphasizing its high predictability.
Spectral regions and peaks with the highest contribution to the loadings plot [variable importance in projection (VIP) scores i1], ordered by their relative contribution to the model, are shown in Fig. 2(b) . These peaks were quantified and further analysed. Fig. 1(c) shows the percentage of increase or decrease of each selected metabolite between test (samples positive for CMV DNA) and control (not containing CMV DNA) specimens. In turn, Table 1 shows the relative content of each metabolite (displaying a VIP score i1) with respect to the total metabolite content in specimens with or without detectable CMV DNA. Eight out of the 15 metabolites with a VIP score i1 were found to be present in concentrations that differed significantly between test and control specimens. Specifically, two metabolites involved in fatty acid metabolism (total fatty acids, polyunsaturated fatty acids), two extramitochondrial metabolites (lactate, alanine), cell antioxidants (total glutathione) and acetate were upregulated in specimens containing CMV DNA, whereas lysine was downregulated.
Systemic bacterial infections are known to have an impact on the plasma metabolomic profile, which is somewhat reminiscent of that described above (Mickiewicz et al., 2014) . We thus investigated whether the prevalence of bacteraemic infections (due to both Gram-negative and Grampositive micro-organisms) occurring immediately prior to (within the previous week) or within episodes of CMV DNAemia was different from that seen in the absence of CMV DNAemia (within a comparable window of time). Bacteraemia was diagnosed in nine patients with concurrent or subsequent CMV DNAemia and in ten patients not developing CMV DNAemia (P51.0).
Plasma metabolomic profiling for the prediction of the occurrence of CMV DNAemia
We next investigated the power of plasma metabolomics profiling for discriminating between patients who eventually developed CMV DNAemia from those who did not. A total of 134 plasma specimens were available from the former patients (test specimens: median, four specimens; range one to eight specimens). All these specimens were obtained prior to the detection of CMV DNAemia. Most of these (90 %) were collected within the first 30 days after transplantation. In turn, 100 samples obtained within a comparable window of time were available from patients who did not develop CMV DNAemia (control specimens: median, four specimens; range, three to six specimens). Again, a total of 42 metabolites were screened. A PLS-DA model (three latent variables) was built on these samples to discriminate between test and control specimens. A fairly robust metabolic difference was observed between test and control specimens ( Fig. 2a ). The goodness of fit of the model was very high, with an R 2 X (cumulative) of 0.943, and an R 2 Y (cumulative) of 0.861, and its predictability was acceptable (Q 2 cumulative of 0.491).
Spectral regions and peaks with the highest contribution to the loadings plot (VIP scores i1) are shown in Fig. 2 
As shown in Fig. 2 (c) and Table 2 , six out of the ten metabolites with a VIP score i1 were found to be present in concentrations that differed significantly between test and control specimens; these were two cellular antioxidants (taurine, total glutathione; GSx), several microbial metabolites (choline, methylamine, trimethylamine N-oxide; TMAO) and extramitochondrial metabolite (lactate) all of which were significantly upregulated in plasma specimens from patients subsequently developing CMV DNAemia. Lysine and isoleucine were downregulated in test specimens, although statistical significance was not reached. The overall classification accuracy of the PLS-DA model in crossvalidation technical replicates was 73 %.
We next investigated the kinetics of metabolites contributing most significantly to the PLS-DA model (VIP w1 and P value v0.05). This investigation was aimed at determining whether a single time point analysis early after Allo-SCT would allow for the anticipation of the eventual occurrence of CMV DNAemia with sufficient robustness. Fig. 3 shows the kinetics data for the five metabolites most significantly upregulated in test specimens (choline, methylamine, total GSx, TMAO and taurine). The data indicated that overall these metabolites were present in higher concentrations in test specimens than in control specimens from the first week after transplant over the entire follow-up period, although occasionally an inverted ratio of certain metabolites, such as methylamine, taurine and total GSx, was seen at one or more time points. In this context, a PLS-DA model built on specimens obtained at a median of 22 days after Allo-SCT (range 18-28 days) (week 3 in Fig. 3 ) displayed a predictability of 68 % in cross-validation technical replicates. PLS-DA models based on single specimens obtained at other time points performed rather unsatisfactorily (data not shown).
DISCUSSION
To the best of our knowledge, the present study is the first to use plasma metabolomics fingerprinting for anticipating the occurrence of CMV DNAemia and evaluating the potential impact of CMV viraemia in the plasma metabolome in the clinical setting of the Allo-SCT. We identified a plasma metabolomic profile by means of 1 H NMR spectroscopy that may allow the anticipation of the development of CMV DNAemia. By analysing the 1 H NMR spectra of a concentration for a given metabolite in the test group is larger or lower, respectively, than that in the control group. The represented numeric values 6100 correspond to the percentage of increase or decrease for each metabolite. The statistical significance of the differences at the 0.05 level was tested using an ANOVA two-tailed test with Bonferroni correction for multiple testing (*P,0.05; **P,0.01). FA, Fatty acids; PUFA, polyunsaturated fatty acids; UFA, unsaturated fatty acids; GsX, total glutathione; TMAO, trimethylamine N-oxide. number of plasma specimens from patients who eventually developed CMV DNAemia, obtained prior to the detection of plasma CMV DNA, and a set of plasma samples from control patients (not developing CMV DNAemia) we were able to build a fairly robust PLS-DA model that allowed discrimination between test and control samples. The overall classification accuracy (predictability) of this model in cross-validation technical replicates was 73 %. Up to ten metabolites mostly contributed to the model (VIP score i1). Of these, six metabolites were significantly upregulated in specimens from patients who eventually had CMV DNAemia. These were methylamines, especially TMAO, taurine, total GSx and lactate. TMAO is an obligatory downstream metabolite of gut microbiota. Accumulation in the systemic circulation of TMAO has been linked to bacterial translocation, which can occur due to altered intestinal barrier function or bacterial overgrowth (both known to occur in Allo-SCT), and hence to heightened inflammatory responses and oxidative stress . Both taurine and GSx are potent anti-inflammatory molecules that are generated in response to pro-inflammatory states (Tabas & Glass, 2013) . In turn, lactate, a normal end point of the anaerobic breakdown of glucose, has been shown to increase in blood following bacterial LPS administration (Michaeli et al., 2012) ; inflammation triggers CMV reactivation (Cook et al., 2006) , thus it could be hypothesized that the risk of CMV DNAemia in the Allo-SCT setting might be directly related to the net state of systemic inflammation after transplant. In this context, plasma levels of the aforementioned metabolites may be reflective of the magnitude of either systemic inflammation (methylamines), ongoing compensatory antiinflammatory responses (taurine and total GSx) or both. In this sense, both taurine and total GSx are well known cellular antioxidants which are overproduced upon cell injury (Tilton et al., 2011) . In addition, taurine is involved in osmoregulation and cell volume control and can be excreted by the cell in response to the CMV-induced increase in cell volume (Locci et al., 2013) . Kinetics analyses of these metabolites (and overall that of all metabolites displaying VIP scores i1 in the PLS-DA model) revealed that the plasma metabolomics signature described by our PLS-DA model was identifiable quite early after Allo-SCT (between 1 and 2 weeks after transplant), although the finest discrimination between test and control specimens was observed when those were obtained at a median of 22 days after AlloS-SCT. In this sense, a PLS-DA model built on specimens obtained at that window of time displayed a predictability of 68 % in crossvalidation technical replicates. It must be stressed, nevertheless, that the strength of our approach resides in the biosignature itself, which is based upon a combination of small metabolic variations, rather than in the concentrations of individual metabolites.
A renewed interest in antiviral prophylaxis for the prevention of CMV-related morbidity following Allo-SCT has recently emerged due to the advent of new drugs with increased intrinsic activity against CMV and better safety profiles in comparison with classical anti-CMV drugs (Boeckh et al., 2015) . The main goal of antiviral prophylaxis is to abrogate CMV replication in tissues and organs harbouring the virus in a latent state, avoiding virus dissemination to the systemic compartment. Since universal prophylaxis strategies lead inevitably to overtreatment, the identification of biomarkers anticipating the occurrence of CMV viraemia would allow the inception of antiviral prophylaxis on an individual basis according to the patient's risk (targeted prophylaxis). The potential clinical significance of our findings remains to be proven and should be weighted in this particular context.
A chemometric PLS-DA model built on samples with and without detectable CMV DNA showed a good discriminative power and predictability (the classification accuracy of this model in cross-validation technical replicates was 81 %), and revealed the presence of metabolites that appeared to be upregulated during active systemic CMV infection. Fatty acid metabolism, tricarboxylic acid cycle (TCA), oxidative stress response and microbial metabolism are among the metabolic cores that were found to be closely associated with the presence of CMV DNAemia. Although the interpretation of metabolic profiles in terms of global metabolism is not straightforward, our results suggested increased metabolic fluxes for glycolysis, TCA and fatty acid biosynthesis during episodes of CMV DNAemia. We observed increased levels of alanine, lactate and total fatty acids and a shift in the fatty acid profile towards unsaturated species. Our data, however, do not conclusively prove that CMV replication was the force specifically driving the reported changes in the plasma metabolome. In this context, no plasma specimens obtained at the time of CMV DNAemia clearance were analysed. In this sense, reversal of the plasma metabolomic profile associated with CMV DNAemia would have provided a stronger causal link between CMV replication and the specific metabolome profile described. Experiments addressing this issue are currently under way. Previous in vitro studies reported increased levels of alanine and acetyl-CoA and increased fatty acid biosynthesis in human fibroblasts infected with CMV, probably related to disruption of mitochondrial networks (Munger et al., 2008; Vastag et al., 2011) . The metabolomic pattern found in CMV infected cells in vitro does not entirely overlap with that found in the current study in human plasma specimens. It is likely that other factors, in addition to CMV replication itself, may have an impact on the metabolomics signature found in plasma specimens from patients with CMV viraemia. In this context, the occurrence of bacteraemia, known to have an impact on the plasma metabolomic profile somehow reminiscent to that described above (Mickiewicz et al., 2014) , either immediately prior to or during active CMV infection, however, did not appear to have contributed significantly to this effect in our cohort. Nevertheless, this extent cannot be definitively ruled out by our data. In addition, the incidence rate of GvHD, which may also have an impact on the plasma metabolome, was not significantly different in patients with or without CMV DNAemia. Nevertheless, further studies are required to consistently demonstrate that CMV is directly responsible of these changes in the plasma metabolome.
It is of note that the plasma metabolomic profile reported herein is also reminiscent, although not entirely overlapping, to that observed in urine from newborns with congenital CMV infection (Locci et al., 2013) .
Limitations of the current study are the following: (i) the study cohort was relatively small for this type of study; (ii) patients in the current cohort were relatively heterogeneous in terms of demographics (age, in particular) and known risk factors for CMV viraemia and CMV end-organ disease, such as the type of transplant, the source of stem cells and the presence or absence of GvHD; nevertheless, none of these factors was significantly associated with the occurrence of CMV DNAemia in the current cohort; and (iii) no crossvalidation analyses using samples from an independent cohort were performed; this seems a stringent requirement for validation of our data. Studies addressing this issue are currently under way.
In summary, the data suggest that plasma metabolomics profiling may allow early identification of Allo-SCT recipients prone to develop active systemic CMV infection, and in this sense it could be a useful ancillary tool for guiding the inception of antiviral prophylaxis (targeted prophylaxis).
In addition, our study revealed interesting insights about the potential effect of active systemic CMV infection in the host metabolome. Whether this knowledge may be of interest in the clinical management of CMV infection in this transplant setting remains to be determined.
METHODS
Patients. The current cohort consisted of 53 non-consecutive patients who underwent Allo-SCT for haematological disorders at the Haematology unit of the Hospital Clínico Universitario (HCU) of Valencia between 2010 and 2013. The lack of available plasma specimens for metabolomics profiling was the only criterion for patient exclusion. The median age of patients was 49 years (range 18-69 years). Relevant clinical and demographic data of the patients are summarized in Table 3 . The study period comprised the first 100 days following transplantation. Only initial (first) episodes of CMV DNAemia (active systemic CMV infection) were considered for the analyses described herein. The study was approved by the HCU-Fundació n INCLIVA Ethics Committee. All patients gave their informed consent to participate in the study.
Management of active CMV infection. Monitoring of plasma CMV DNAemia was performed by real-time PCR (CMV real-time PCR or Abbott RealTime CMV; Abbott Molecular) as previously described (Giménez et al., 2014; Tormo et al., 2011) . The limits of detection and quantification of both assays are approximately 20 copies ml 21 (95 % confidence interval). Patients were treated preemptively with antivirals following a previously detailed protocol (Giménez et al., 2014; Tormo et al., 2011) . Briefly, pre-emptive antiviral therapy with oral valganciclovir (900 mg over 12 h), intravenous ganciclovir (5 mg kg 21 over 12 h) or intravenous foscarnet (60 mg kg 21 over 12 h) was initiated upon detection of either a CMV DNA load w500 copies ml 21 (when CMV surveillance was performed with the CMV PCR kit; until May 2012) or w1000 copies ml 21 (when CMV monitoring was performed with the new Abbott DThe statistical significance of the differences was tested using the ANOVA test with Bonferroni correction for multiple testing. P,0.005 was considered significant.
Real Time CMV assay; since May 2012), and discontinued after two consecutive negative (undetectable) PCR results. CMV monitoring was performed at least once a week until day 100. Plasma CMV DNAemia values were normalized to the first WHO International Standard for CMV for Nucleic Acid Amplification (NAT)-Based Assays (National Institute for Biological Standards and Control), and reported in IU ml 21 . The conversion factor (copies ml 21 to IU ml 21 ) for each real-time PCR assay was calculated previously (Clari et al., 2013) .
Definitions. A bloodstream bacterial infection (bacteraemia) was defined as the isolation of a bacterial pathogen from at least one blood culture. Two sets of blood cultures (BD BACTEC Plus Aerobic/F and BD BACTEC Plus Anaerobic/F; Becton Dickinson) were drawn upon occurrence of fever (w37 uC) and/or the presence of clinical signs or symptoms of infection. For coagulase-negative staphylococci and other common skin contaminants, two sets of positive blood cultures were required.
Plasma sample collection. Whole blood was collected by arm venepuncture between 8 . 00 and 9 . 00 into EDTA-treated collection tubes. The patients had not intentionally exercised in the 3 days prior to sampling, and continued to eat their habitual diet without unusual deviations. After mixing carefully, the samples were centrifuged (within the next 60 min following blood collection) at approximately 1000 g for 10-15 min. Plasma were then separated and an aliquot conserved (less than 1 h after separation) at 280 uC until metabolomic analysis. Plasma employed for metabolomic analysis had not been thawed previously (Kamlage et al., 2014) .
NMR spectroscopy. Plasma specimens were thawed on ice immediately before metabolomics sample preparation and profiling. Fifty microlitres of D 2 O were added to 500 ml plasma and an aliquot of 500 ml was taken and placed in a 5 mm NMR tube. This procedure was performed by an automatic sample handler Gilson 215 (Gilson) and took no longer than 2 min per sample. Thawed samples were kept at 6 uC in a SampleJet (Bruker GmbH) sampler exchanger before measurement and never longer than 2 h. 1 H-NMR spectra were recorded in a Bruker Avance DRX 600 spectrometer (Bruker GmbH) operating at 600.13 MHz with a 1 mm 1 H/ 13 C/ 15 N TX1 probe, calibrated using standard reference samples of alanine 10 mM and creatine 10 mM. Field homogeneity was tuned by semi-automated shimming for each sample following the instructions of the manufacturer. Samples were measured at 37 uC. A single-pulse presaturation experiment was acquired in all samples. A total of 256 FIDs (free induction decay) were collected into 64 000 data points with a spectral width of 14 p.p.m. and the recycle delay of 1 s. Water signal was saturated with a weak irradiation during the recycle delay. Before Fourier transformation, the free induction decay was multiplied by a 0.3 Hz exponential line broadening. Spectral chemical shift referencing on the alanine CH 3 doublet signal at 1.475 p.p.m. was performed in all spectra. We normalized the binned data to total spectral area. We used available spectral databases and two-dimensional NMR experiments to aid structural identification of relevant metabolites. All spectra were processed using MNova (MestreLab) and transferred to MATLAB (MathWorks) using in-house scripts for data analysis. NMR has been shown to display w98 % reproducibility (Dumas et al., 2006; Bodi et al., 2012, D. Monleó n, unpublished data), allowing systematic detection of small changes (even v5 %). Metabolomics analysis. The chemical shift regions including resonances between 0.50 and 4.70 and between 5.5 and 9.5 were investigated. The EDTA regions (2.53-2.58, 3.1-3.3 and 3.6-3.7 p.p.m.) were also excluded from the bucketing and multivariate analysis. The spectra were normalized to total aliphatic spectral area to eliminate differences in metabolite total concentration. The spectra were binned into 0.01 p.p.m. buckets (6 Hz) and mean centred for multivariate analysis. Projection to latent structures for discriminant analysis (PLS-DA) was applied to binned NMR spectra datasets (PLSToolbox; Eigenvector) for detecting differential biosignatures (Trygg et al., 2007) . The main advantage of PLS-DA models is that the main sources of variability in the data are modelled by the so-called latent variables, and consequently, in their associated scores and loadings, allowing the visualization and understanding of different patterns and relations in the data (Trygg et al., 2007) . From a mathematical point of view, PLS-DA is a supervised extension of principal component analysis used to distinguish two or more classes by searching for variables (X matrix) that are correlated with class membership (Y matrix). In this approach the axes are calculated to maximize class separation and can be used to examine separation that would otherwise be across three or more principal components. For evaluation of accuracy of the models, cross-validation was performed on the whole dataset. Cross-validation enables an assessment of the optimal complexity of a model and allows an estimation of the performance of a model when it is applied to unknown data. For a given dataset, cross-validation involves a series of experiments, hereby called subvalidation experiments, each of which involves the removal of a subset of individuals from a dataset, construction of a model using the remaining objects in the dataset, and subsequent application of the resulting model to the removed objects. Therefore, each subvalidation experiment involves testing a model with objects that were not used to build the model. Typical cross-validation involves more than one subvalidation experiment by selection of different subsets of individuals for model building and model testing. In this study, PLS-DA models were cross-validated by technical replication of the whole process on 25 random data splits. The accuracy was calculated by averaging the classification success of all these technical replicates on the selected set of samples. The quality of the models is described by R 2 X, R 2 Y and Q 2 . R 2 X or R 2 Y is defined as the proportion of variance in the data explained by the models and indicates goodness of fit (ranging from 0 to 1; the model improves as approaches to 1). Q 2 is defined as the proportion of variance in the data predictable by the model and thus indicates predictability, calculated by cross-validation procedure (Holmes et al., 2008) . Although Q 2 also ranges between 0 and 1, it usually is lower than 0.7 as the value reaches a plateau when data are overfitted. More detail about the chemometric modelling can be found elsewhere (Bodi et al., 2012; Borrás et al., 2011) . Signals belonging to the metabolites contributing the most to VIP scores in the models (VIP i1) were integrated and quantified using semiautomated in-house MATLAB 7.4 (Mathworks) peak-fitting routines. These fitting routines were based on Levenburg-Marquard optimization procedures. The target function for the optimization included experimental spectra measured for standard solutions of selected metabolites with complex multiplet patterns and theoretically generated Lorentzian-shape signals for those metabolites with simpler spectral patterns. The metabolic levels were expressed as total relative metabolic content (calculated as the integral of the selected metabolite divided by the sum of all integrals in the spectra). The statistical significance of the differences at the 0.05 level was tested using an ANOVA two-tailed test with Bonferroni correction for multiple testing. Statistical analyses were performded using SPSS 15.0 (SPSS) and GraphPad Statmate 5.0 (GraphPad Software). 
